Smith+Nephew to announce 2024 full year results February 25

Smith+Nephew PLC (LSE: SN, NYSE: SNN), a leading medical technology company with a "GOOD" Financial Health score according to InvestingPro, is scheduled to release its full year results for the period ending December 31, 2024, on Tuesday, February 25, 2025. The announcement, set for 7.00am GMT / 2.00am EDT, will be followed by a conference call for financial analysts at 8.30am GMT / 3.30am EDT.

The company, which operates in over 100 countries and generated annual sales of $5.5 billion in 2023, is known for its medical devices focused on the repair, regeneration, and replacement of soft and hard tissue. With a history dating back to 1856, Smith+Nephew continues to serve the healthcare industry with its innovative product offerings across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Smith+Nephew’s upcoming financial disclosure is anticipated by investors and analysts who track the performance of the medical technology sector. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, with analysts expecting net income growth this year.

The company’s results will provide insights into its operational and financial health, as well as its strategic direction in the face of global market conditions, including economic and financial trends, regulatory changes, and competitive dynamics. For deeper insights, investors can access comprehensive Pro Research Reports covering 1,400+ top stocks, including Smith+Nephew, on InvestingPro.

The company has advised interested parties to visit its website for details regarding the conference call. The website will also provide access to the company’s history, product information, and other investor resources.

This announcement is based on a press release statement and contains forward-looking statements regarding expected revenue growth, market trends, and product development. These statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

Investors and stakeholders are reminded that forward-looking statements involve risks and uncertainties, including but not limited to economic conditions, regulatory actions, product quality, supply chain stability, and competitive factors. Smith+Nephew does not assume any obligation to update any forward-looking statement in light of new information or future events.

Further details about the company, including its history, operations, and product offerings, can be found at www.smith-nephew.com. The company is a constituent of the FTSE100 and is listed on both the London Stock Exchange (LON:LSEG) and the New York Stock Exchange under the tickers SN and SNN, respectively.

In other recent news, Smith+Nephew, a global medical technology company, has announced the appointment of Sybella Stanley as an independent Non-Executive Director, effective February 1, 2025. Stanley, with her extensive experience from her tenure at RELX Plc, will join the Remuneration Committee and is set to become its Chair on June 30, 2025. These developments are part of the company’s commitment to effective succession planning and assembling a diverse range of talent.

In parallel, Berenberg has downgraded its rating on Smith & Nephew from a Buy to a Hold, following the company’s release of a third-quarter trading report. The report indicated slower than expected growth in the US Orthopaedics business and increased difficulties in China, prompting downgrades in its guidance for the years 2024 and 2025. Berenberg’s revised position reflects a more cautious stance on the company’s outlook, leading to a reduction in the price target to £10.50 from £14.50.

These developments are part of recent shifts within Smith+Nephew. The company has been working on a recovery strategy, but the pace of recovery is not meeting expectations, raising doubts about the potential impact of the management’s 12-point strategy in the medium term.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.